These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 6805547)

  • 21. The use of serum creatine phosphokinase in genetic counseling for Duchenne muscular dystrophy. I. Analysis of results from 29 studies.
    Gale AN; Murphy EA
    J Chronic Dis; 1978 Feb; 31(2):101-9. PubMed ID: 659567
    [No Abstract]   [Full Text] [Related]  

  • 22. Racial effect on serum creatine-kinase: implications for estimation of heterozygosity risks for females at-risk for Duchenne dystrophy.
    Passos-Bueno MR; Rabbi-Bortolini E; Azevêdo E; Zatz M
    Clin Chim Acta; 1989 Feb; 179(2):163-8. PubMed ID: 2920447
    [No Abstract]   [Full Text] [Related]  

  • 23. A method for the detection of carriers of Duchenne muscular dystrophy--a preliminary report.
    Monckton G; Marusyk H; Pehowich E
    Am J Hum Genet; 1981 Nov; 33(6):978-86. PubMed ID: 7325161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Duchenne muscular dystrophy. Genetic aspects, carrier detection and antenatal diagnosis.
    Emery AE
    Br Med Bull; 1980 May; 36(2):117-22. PubMed ID: 7020836
    [No Abstract]   [Full Text] [Related]  

  • 25. Carrier detection in X-linked recessive (Duchenne) muscular dystrophy: serum creatine phosphokinase values in premenarchal, menstruating, postmenopausal and pregnant normal women.
    Smith I; Elton RA; Thomson WH
    Clin Chim Acta; 1979 Nov; 98(3):207-16. PubMed ID: 498534
    [No Abstract]   [Full Text] [Related]  

  • 26. [A case of an 8-year-old girl, a symptomatic carrier of Duchenne's muscular dystrophy].
    Kurihara M; Imai Y; Kumagai K; Hasegawa H; Nonaka M
    No To Hattatsu; 1990 Jul; 22(4):394-6. PubMed ID: 2400617
    [No Abstract]   [Full Text] [Related]  

  • 27. Genetic counseling in Duchenne muscular dystrophy.
    Bradley WG; Kelemen J
    Muscle Nerve; 1979; 2(5):325-8. PubMed ID: 492208
    [No Abstract]   [Full Text] [Related]  

  • 28. A new method for the analysis of age trends in CPK levels with application to Duchenne muscular dystrophy.
    Lange K; Zatz M
    Hum Hered; 1979; 29(3):154-60. PubMed ID: 468274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of Duchenne muscular dystrophy carriers: quantitative echography and creatine kinasemia.
    Schapira G; Laugier P; Rochette J; Berger G; Katz P; Perrin J
    Hum Genet; 1987 Jan; 75(1):19-23. PubMed ID: 3542803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Screening for elevated creatine kinase activities for the early diagnosis of Duchenne muscular dystrophy].
    Beckmann R; Scheuerbrandt G
    Fortschr Med; 1979 Oct; 97(39):1733-6. PubMed ID: 511067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The significance of different types of information in calculating the probability that a female relative of a Duchenne muscular dystrophy patient is a carrier.
    ten Kate LP; Offringa PJ
    Clin Genet; 1981 Oct; 20(4):281-8. PubMed ID: 7333021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Carrier detection in Duchenne muscular dystrophy. Evidence from a study of obligatory carriers and mothers of isolated cases.
    Sibert JR; Harper PS; Thompson RJ; Newcombe RG
    Arch Dis Child; 1979 Jul; 54(7):534-7. PubMed ID: 485196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estimates of conditional heterozygosity risks for young females in Duchenne muscular dystrophy.
    Passos-Bueno MR; Otto PA; Zata M
    Hum Hered; 1989; 39(4):202-11. PubMed ID: 2583732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Editorial: Carrier detection in Duchenne type muscular dystrophy.
    Morgan G
    Aust N Z J Med; 1974 Apr; 4(2):196-7. PubMed ID: 4528526
    [No Abstract]   [Full Text] [Related]  

  • 35. Lymphocyte capping and carrier detection in Duchenne muscular dystrophy.
    Br Med J; 1978 Dec; 2(6152):1589-90. PubMed ID: 728736
    [No Abstract]   [Full Text] [Related]  

  • 36. The use of serum creatine phosphokinase in genetic counseling for Duchenne muscular dystrophy. II. Review of methods of assay and factors which may be relevant in the interpretation of serum creatine phosphokinase activity.
    Gale AN; Murphy EA
    J Chronic Dis; 1979; 32(9-10):639-51. PubMed ID: 489704
    [No Abstract]   [Full Text] [Related]  

  • 37. Duchenne muscular dystrophy: carrier detection by ultrasound.
    Steinbicker V; von Rohden L; Krebs P; Szibor R
    Lancet; 1984 Jun; 1(8392):1463. PubMed ID: 6145895
    [No Abstract]   [Full Text] [Related]  

  • 38. Asymptomatic hyperCKemia: detection of an isolated carrier of Duchenne muscular dystrophy.
    Tachi N; Wakai S; Yutoh Y; Chiba S; Miura J
    J Child Neurol; 1990 Oct; 5(4):351-3. PubMed ID: 2246492
    [No Abstract]   [Full Text] [Related]  

  • 39. New mutations in Duchenne muscular dystrophy.
    Lane RJ; Partridge T; Rose FC
    Lancet; 1988 Oct; 2(8617):971-2. PubMed ID: 2902424
    [No Abstract]   [Full Text] [Related]  

  • 40. Activity of creatine kinase in sera from healthy women, carriers of Duchenne muscular dystrophy and cord blood, determined by the "European" recommended method with NAC-EDTA activation.
    Moss DW; Whitaker KB; Parmar C; Heckmatt J; Wikowski J; Sewry C; Dubowitz V
    Clin Chim Acta; 1981 Oct; 116(2):209-16. PubMed ID: 6794955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.